Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome

Annals of Hematology

Volumn 93, Issue 6, 2014, Pages 957-963

  Iriyama, Noriyoshi ^a   Asou, Norio ^b,c   Miyazaki, Yasushi ^d   Yamaguchi, Shunichiro ^c   Sato, Shinya ^e   Sakura, Toru ^f   Maeda, Tomoya ^b   Handa, Hiroshi ^g   Takahashi, Masatomo ^h   Ohtake, Shigeki ⁱ   Hatta, Yoshihiro ^a   Sakamaki, Hisashi ^j   Honda, Sumihisa ^k   Taki, Tomohiko ^l   Taniwaki, Masafumi ^m   Miyawaki, Shuichi ⁿ   Ohnishi, Kazunori ^o   Kobayashi, Yukio ^p   Naoe, Tomoki ^q  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^c KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^d NAGASAKI UNIVERSITY   (Japan)

^e Sasebo Shiritsu Sogo Hospital   (Japan)

^f SAISEIKAI MAEBASHI HOSPITAL   (Japan)

^g GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^j TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^k NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^l KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^m KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

ⁿ Tokyo Metropolitan Ohtsuka Hospital   (Japan)

^o HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^p NATIONAL CANCER CENTER HOSPITAL   (Japan)

^q NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

more..

Author keywords

CD15; CD34; CD7; CEBPA; HLA DR; Normal karyotype acute myeloid leukemia; Prognostic factor

Indexed keywords

CD15 ANTIGEN; CD34 ANTIGEN; CD7 ANTIGEN; CYTARABINE; HLA DR ANTIGEN; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER PROGNOSIS; CEBPA GENE; FEMALE; GENE; GENE MUTATION; HUMAN; IMMUNOPHENOTYPING; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD15; ANTIGENS, CD34; ANTIGENS, CD7; ANTIMETABOLITES, ANTINEOPLASTIC; CCAAT-ENHANCER-BINDING PROTEINS; CYTARABINE; FEMALE; FUCOSYLTRANSFERASES; HLA-DR ANTIGENS; HUMANS; IMMUNOPHENOTYPING; KAPLAN-MEIER ESTIMATE; KARYOTYPE; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902345070     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2013-4     Document Type: Article

References (29)

1. MasonKD, Juneja SK, Szer J (2006) The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis? Blood Rev 20(2):71-82
2. IriyamaN, Hatta Y, Takeuchi J, Ogawa Y, Ohtake S, Sakura T, Mitani K, Ishida F, Takahashi M, Maeda T, Izumi T, Sakamaki H, Miyawaki S, Honda S, Miyazaki Y, Taki T, Taniwaki M, Naoe T (2013) CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21). Leuk Res 37(9):1021-1026
3. Montesinos P, Rayón C, Vellenga E, Brunet S, González J, González M, Holowiecka A, Esteve J, Bergua J, González JD, Rivas C, Tormo M, Rubio V, Bueno J, Manso F, Milone G, de la Serna J, Pérez I, Pérez-Encinas M, Krsnik I, Ribera JM, Escoda L, Lowenberg B, Sanz MA, PETHEMA, HOVON Groups (2011) Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood 117(6):1799-1805
4. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92(7):2322-2333 (Pubitemid 28452973)
5. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96(13):4075-4083
6. Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD, Cancer and Leukemia Group B (CALGB 8461) (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100(13):4325-4336
7. Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM, van Marwijk KM, Wijermans P, Schouten H, Huijgens PC, van der Lelie H, Fey M, Ferrant A, Maertens J, Gratwohl A, Lowenberg B (2007) Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 109(9):3658-3666 (Pubitemid 46641712)
8. Yanada M, Matsuo K, Emi N, Naoe T (2005) Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 103(8):1652-1658 (Pubitemid 40490026)
9. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H, Appelbaum FR, Döhner H, Antin JH, Soiffer RJ, Cutler C (2009) Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 301(22):2349-2361
10. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H, German-Austrian Acute Myeloid Leukemia Study Group (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358(18):1909-1918 (Pubitemid 351620111)
11. Fröhling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, Tobis K, Döhner H, Döhner K (2004) CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22(4):624-633
12. Döhner K, Schlenk RF, Habdank M, Scholl C, Rücker FG, Corbacioglu A, Bullinger L, Fröhling S, Döhner H (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 106(12):3740-3746
13. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, Haferlach T, Hiddemann W, Falini B (2005) Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106(12):3733-3739 (Pubitemid 41739006)
14. Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S (2008) Prognostic relevance of FLT3-TKD mutations in AML: the combination matters -an analysis of 3082 patients. Blood 111(5):2527-2537
15. Lin LI, Chen CY, Lin DT, Tsay W, Tang JL, Yeh YC, Shen HL, Su FH, Yao M, Huang SY, Tien HF (2005) Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 11(4):1372-1379 (Pubitemid 40326229)
16. Röhrs S, Scherr M, Romani J, Zaborski M, Drexler HG, Quentmeier H (2010) CD7 in acute myeloid leukemia: correlation with loss of wild-type CEBPA, consequence of epigenetic regulation. J Hematol Oncol 3:15
17. Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R, Japan Adult Leukemia Study Group AML 97 Study (2005) A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study. Cancer 104(12):2726-2734 (Pubitemid 41799616)
18. Sakamaki H, Miyawaki S, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, TakahashiM, Ogawa Y, Honda S, Ohno R (2010) Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study. Int J Hematol 91(2):284-292
19. Tominaga-Sato S, Tsushima H, Ando K, Itonaga H, Imaizumi Y, Imanishi D, Iwanaga M, Taguchi J, Fukushima T, Yoshida S, Hata T, MoriuchiY, Kuriyama K, Mano H, Tomonaga M, Miyazaki Y (2011) Expression of myeloperoxidase and gene mutations in AML patients with normal karyotype: double CEBPAmutations are associated with high percentage of MPO positivity in leukemic blasts. Int J Hematol 94(1):81-89
20. Nanri T, Uike N, Kawakita T, Iwanaga E, Mitsuya H, Asou N (2010) A family harboring a germ-line N-terminal C/EBPalphamutation and development of acute myeloid leukemia with an additional somatic C-terminal C/EBPalphamutation.Genes Chromosome Cancer 49(3):237-241
21. Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C, Heerema NA, Hirsch B, Raimondi SC, Lange B, Franklin JL, Radich JP, Meshinchi S (2009) Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children 's Oncology Group. Blood 113(26):6558-6566
22. Döhner K, Döhner H (2008) Molecular characterization of acute myeloid leukemia. Haematologica 93(7):976-982
23. Rausei-Mills V, Chang KL, Gaal KK, Weiss LM, Huang Q (2008) Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation. Am J Clin Pathol 129(4):624-629 (Pubitemid 352029282)
24. Li X, Li J, Du W, Zhang J, Liu W, Chen X, Li H, Huang S, Li X (2011) Relevance of immunophenotypes to prognostic subgroups of age, WBC, platelet count, and cytogenetics in de novo acute myeloid leukemia. APMIS 119(1):76-84
25. Ferrari A, Bussaglia E, Úbeda J, Facchini L, Aventin A, Sierra J, Nomdedéu JF (2012) Immunophenotype distinction between acute promyelocytic leukaemia and CD15-CD34- HLA-DR- acute myeloid leukaemiawith nucleophosminmutations.Hematol Oncol 30(3):109-114
26. De J, Zanjani R, Hibbard M, Davis BH (2007) Immunophenotypic profile predictive of KIT activating mutations in AML1-ETO leukemia. Am J Clin Pathol 128(4):550-557 (Pubitemid 47584431)
27. Wouters BJ, Löwenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, Delwel R (2009) Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 113(13):3088-3091
28. Cammenga J, Mulloy JC, Berguido FJ, MacGrogan D, Viale A, Nimer SD (2003) Induction of C/EBPalpha activity alters gene expression and differentiation of human CD34+ cells. Blood 101(6):2206-2214 (Pubitemid 36302059)
29. Miyawaki S (2012) Clinical studies of acute myeloid leukemia in the Japan Adult Leukemia Study Group. Int J Hematol 96(2):171-177